Medicare AdvantageCoverageMedium impact
MA08.085j, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology, Pediatrics·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialized cancer medication. This change affects the approval requirements and coverage guidelines for this drug used in acute lymphoblastic leukemia treatment.
Action Required
By August 25, 2025: Billing team and oncology providers must review and update prior authorization requirements for Rylaze® prescriptions under Medicare Advantage plans. Update EMR templates to ensure medical necessity documentation meets the new criteria. Verify current authorizations are still valid under updated guidelines.